Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENINSULA: First-line pembrolizumab + platinum/pemetrexed + lenvatinib for unresectable malignant pleural mesothelioma
jRCT2051230209Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, lenvatinib, carboplatin, cisplatin and pemetrexed in pleural mesothelioma, sponsored by Merck & Co. Primary endpoint: Tumor response rate. Started May 2024; status: recruiting.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2051230209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230209.